Surabhi B Vora
Overview
Explore the profile of Surabhi B Vora including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bucayu R, Boge C, Yildirim I, Aviles-Robles M, Vora S, Berman D, et al.
J Pediatric Infect Dis Soc
. 2024 Nov;
13(12):633-638.
PMID: 39513400
Of 319 children with invasive candidiasis, 67 (21%) transitioned from intravenous to enteral antifungal therapy. Eight (12%) transitioned back to intravenous antifungal therapy, one due to perceived treatment failure defined...
2.
Szewczyk W, Fitzpatrick A, Fossou H, Gentile N, Sotoodehnia N, Vora S, et al.
BMC Infect Dis
. 2024 Nov;
24(1):1241.
PMID: 39497076
Background: Recovery from SARS CoV-2 infection is expected within 3 months. Long COVID occurs after SARS-CoV-2 when symptoms are present for more than 3 months that are continuous, relapsing and...
3.
Otto W, Vora S, Dulek D
J Pediatric Infect Dis Soc
. 2024 Feb;
13(Supplement_1):S22-S30.
PMID: 38417088
Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in pediatric transplantation. However, currently utilized CMV prevention paradigms have limitations, leading to research aimed at novel strategies for mitigation...
4.
Willis Z, Oliveira C, Abzug M, Anosike B, Ardura M, Bio L, et al.
J Pediatric Infect Dis Soc
. 2024 Feb;
13(3):159-185.
PMID: 38339996
Background: Since November 2019, the SARS-CoV-2 pandemic has created challenges for preventing and managing COVID-19 in children and adolescents. Most research to develop new therapeutic interventions or to repurpose existing...
5.
Wattier R, Bucayu R, Boge C, Ross R, Yildirim I, Zaoutis T, et al.
J Pediatric Infect Dis Soc
. 2023 Aug;
12(9):487-495.
PMID: 37589394
Background: Adjunctive diagnostic studies (aDS) are recommended to identify occult dissemination in patients with candidemia. Patterns of evaluation with aDS across pediatric settings are unknown. Methods: Candidemia episodes were included...
6.
Crumm C, Brown E, Vora S, Lowry S, Schlatter A, Rutman L
Pediatr Emerg Care
. 2023 Jun;
39(8):580-585.
PMID: 37391189
Objectives: Previous research has shown racial, ethnic, and socioeconomic disparities in provider medical evaluations and reporting to child protective services (CPS) and law enforcement (LE) for cases of suspected child...
7.
Sherman G, Lamb G, Sharma T, Lloyd E, Nagel J, Dandam N, et al.
J Pediatric Infect Dis Soc
. 2023 Mar;
12(3):152-155.
PMID: 36928172
Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals...
8.
Vora S, Englund J, Trehan I, Waghmare A, Kong A, Adler A, et al.
Pediatr Infect Dis J
. 2022 Dec;
42(1):32-34.
PMID: 36476522
Multiple antiviral and monoclonal antibody therapies are now available for mild-moderate COVID-19 in high-risk patients ≥12 years of age. However, data for the use of these agents in children is...
9.
McLaughlin S, Vora S, Church E, Spitters C, Thyer A, LaCourse S, et al.
F S Rep
. 2022 Oct;
3(3):285-291.
PMID: 36212574
Objective: To report 2 cases of adverse pregnancy outcomes due to delayed diagnosis of urogenital tuberculosis and propose a screening algorithm for patients from tuberculosis-endemic countries. Design: Case report. Setting:...
10.
Wolf J, Abzug M, Anosike B, Vora S, Waghmare A, Sue P, et al.
J Pediatric Infect Dis Soc
. 2022 Feb;
11(5):177-185.
PMID: 35107571
Background: Starting in November 2020, the US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) for multiple novel virus-neutralizing monoclonal antibody therapies, including bamlanivimab monotherapy (now revoked),...